Clinical Trial Update: Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study is evaluating the combination of mezigdomide and talquetamab in relapsed and refractory multiple myeloma and is currently recruiting. This trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Mezigdomide (mezigdomide)
• Talquetamab (talquetamab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Status: RECRUITING